Skip to content

Above 180/120? See warning signs

SevereHypertension

An antihypertensive drug improves corticosteroid – based skin treatments

Severe Hypertension NetworkPublished March 18, 20155 min read
An antihypertensive drug improves corticosteroid - based skin treatments

Key points

  • Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, “Cordeliers Research Centre”) to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases.
  • Corticosteroid-based dermatological creams are indicated for the symptomatic treatment of inflammatory skin conditions, such as atopic dermatitis and psoriasis, for example.
  • Application of corticosteroids to cultured skin causes it to become thinner: in 6 days, the thickness of the epidermis was reduced by one-third.
  • The results obtained show that adding spironolactone to the corticosteroid significantly limits skin atrophy.

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, “Cordeliers Research Centre”) to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases.

This work is published in the Journal of Investigative Dermatology.

Corticosteroid-based dermatological creams are indicated for the symptomatic treatment of inflammatory skin conditions, such as atopic dermatitis and psoriasis, for example. However, they have frequent side effects, such as a slight burning sensation, and very often end by inducing skin atrophy (thinning of the skin, which becomes fragile), which is inconvenient for the patient, and for which there is presently no treatment.

The researchers from Inserm formulated a hypothesis whereby this harmful effect might be related to the inappropriate activation by these creams of mineralocorticoid receptors located in the epidermis. These receptors, which are present in the kidney, heart, eye, and certain neurons in particular, reacted with aldosterone, a hormone that regulates the blood pressure. Moreover, previous studies also showed them to be highly sensitive to corticosteroids.

Application of corticosteroids to cultured skin causes it to become thinner: in 6 days, the thickness of the epidermis was reduced by one-third. The researchers then induced a pharmacological blockade of the receptors by adding specific antagonists to the corticosteroid treatment. The inability of the corticosteroid to bind to the mineralocorticoid receptors restores proliferation of the epidermal cells, and partially corrects epidermal atrophy.

From the clinical point of view, it turns out that spironolactone, a drug used for a very long time as an antihypertensive drug (and which has marketing authorisation), is an antagonist of the mineralocorticoid receptor. The researchers therefore tested a treatment based on spironolactone for 28 days in 23 healthy volunteers. Creams of different composition were applied to 4 areas of their arms:

a cream containing a corticosteroid used in dermatology
a cream containing spironolactone
a combination of both drugs
a placebo

The results obtained show that adding spironolactone to the corticosteroid significantly limits skin atrophy.

For Nicolette Farman, “This is a highly original piece of work, at the crossroads between endocrinology and dermatology, and brings together researchers in basic science and clinicians. Now it remains to reformulate this old drug for a new application, and test this product in patients with various skin diseases in order to confirm the reduction in side effects from corticosteroids without loss of efficacy.”

###

Sources

Topical mineralocorticoid receptor blockade limits glucocorticoid-induced epidermal atrophy in human skin.

Eve Maubec MD-PhD a,b, Cédric Laouénan* MD b,c,d, Lydia Deschamps* MD e, Van Tuan Nguyen* MS f,g, Isabelle Scheer-Senyarich* a PhD, Anne-Catherine Wackenheim-Jacobs MD h, Maud Steff MD a,b, Stéphanie Duhamel MS g,i, Sarah Tubiana PharmD b,c,n, Nesrine Brahimi MD a, Stéphanie Leclerc-Mercier MD j, Béatrice Crickx MD-PhD a,b, Claudine Perret MSc g,i, Selim Aractingi, MD-PhD k,l, Brigitte Escoubet MD-PhD b,i,m, Xavier Duval MD- PhD b,c,n, Philippe Arnaud PharmD-PhD p,q,r,s, Frederic Jaisser MD-PhD g,i, France Mentré MD-PhD b,c,d, Nicolette Farman MD-PhD g,i.

a Assistance Publique Hôpitaux de Paris (APHP), Hôpital Bichat Claude Bernard, Département de Dermatologie, Paris, France
b Université Paris Diderot, Sorbonne Paris Cité, Paris, France
c UMR 1137, INSERM, IAME, Paris, France.
d APHP, Hôpital Bichat Claude Bernard, Département de Biostatistiques, Paris, France
e APHP, Hôpital Bichat Claude Bernard, Département d’Anatomopathologie, Paris, France
f UMR 938, INSERM, Centre De Recherches St Antoine, Paris, France
g Université Pierre et Marie Curie, Paris, France
h APHP, Hôpital Bichat Claude Bernard, Département de Radiologie, Paris, France
i UMR 1138, INSERM, Centre de Recherche des Cordeliers, Paris, France
j APHP, Hôpital Necker-Enfants Malades, Département d’Anatomie et Cytologie Pathologiques, Paris, France
k Hôpital Cochin Tarnier, Département de Dermatologie, Paris, France
l Université Paris Descartes, Paris, France
m APHP, Hôpital Bichat Claude Bernard, Département de Physiologie, Paris, France
n APHP, Hôpital Bichat Claude Bernard, Centre d’Investigation Clinique 007, Paris, France.
p APHP, Hôpital Bichat Claude Bernard, Département de Pharmacie, Paris, France
q Université Paris Descartes, Chimie ParisTech, Paris, France
r UMR 8151, CNRS, Paris, France
s UMR 1022, INSERM, Paris, France
* contribution équivalente

The Journal of Investigative Dermatology

Investigator Contact

Nicolette Farman,
Inserm Research Director
Inserm Unit 1138, Centre de Recherche des Cordeliers,
01 44 27 81 04
.(JavaScript must be enabled to view this email address)

###

INSERM (Institut national de la santé et de la recherche médicale)

Journal
Journal of Investigative Dermatology

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. A reading above 180/120 with chest pain, shortness of breath, weakness or vision changes is an emergency: call 911 or your local emergency number.

Energy drinks raise resting blood pressure
Causes of High Blood Pressure

Energy drinks raise resting blood pressure

Healthy young adults who don’t consume caffeine regularly experienced greater rise in resting blood pressure after consumption of a commercially available energy drink – compared to a placebo drink – thus raising the concern that energy drinks may increase the

2 min read

New Guidelines: Treat Obesity First
Causes of High Blood Pressure

New Guidelines: Treat Obesity First

Treat weight problems first, then deal with comorbidities like dyslipidemia, hypertension, and impaired glucose tolerance, a new guideline urges. It’s an entirely new approach to the treatment of disease, said Caroline Apovian, MD, of Boston University, the lead author of

4 min read

Hypertensive crisis

Above 180/120? Know when it’s an emergency.

Wait five minutes and measure again. If your reading is still this high and you have any of these symptoms, call 911 or your local emergency number. Don’t wait to see if it comes down on its own.

  • Chest pain
  • Shortness of breath
  • Back pain
  • Numbness or weakness
  • Change in vision
  • Difficulty speaking

No symptoms but still above 180/120 after a second reading? Contact your doctor straight away. Outside the US, call your local emergency number.